Publication date: 15 May 2018
Source:Bioorganic & Medicinal Chemistry, Volume 26, Issue 9
Author(s): Khushbu Shah, Xin Lin, Sherry F. Queener, Vivian Cody, Jim Pace, Aleem Gangjee
To combine the potency of trimetrexate (TMQ) or piritrexim (PTX) with the species selectivity of trimethoprim (TMP), target based design was carried out with the X-ray crystal structure of human dihydrofolate reductase (hDHFR) and the homology model of Pneumocystis jirovecii DHFR (pjDHFR). Using variation of amino acids such as Met33/Phe31 (in pjDHFR/hDHFR) that affect the binding of inhibitors due to their distinct positive or negative steric effect at the active binding site of the inhibitor, we designed a series of substituted-pyrrolo[2,3-d]pyrimidines. The best analogs displayed better potency (IC50) than PTX and high selectivity for pjDHFR versus hDHFR, with 4 exhibiting a selectivity for pjDHFR of 24-fold.
Graphical abstract
https://ift.tt/2I0l4of
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου